Ataxia Telangiectasia (AT) is a rare autosomal recessive neurodegenerative disorder characterized by progressive cerebellar ataxia, immunodeficiency, telangiectasias (dilated blood vessels in the eyes and skin), and markedly increased susceptibility to malignancies. The disease typically manifests in early childhood with impaired coordination and balance, followed by the development of characteristic telangiectasias around age 5-8. AT is caused by mutations in the ATM gene (Ataxia-Telangiectasia Mutated), which encodes a serine/threonine protein kinase essential for cellular responses to DNA double-strand breaks, oxidative stress, and metabolic homeostasis[@shiloh2021].
The incidence of AT is approximately 1 in 40,000 to 1 in 100,000 live births, with a carrier frequency of approximately 1% in the general population. The disease affects both sexes equally and has been reported worldwide, though founder mutations exist in certain populations. AT represents one of the most severe childhood neurodegenerative disorders, with most individuals requiring wheelchair assistance by adolescence and having a reduced life expectancy[@gatti1993].
The ATM gene (OMIM #607585) is located on chromosome 11q22-23 and spans approximately 150 kb, encoding a 3056 amino acid protein with a molecular weight of ~350 kDa. The ATM protein belongs to the phosphatidylinositol 3-kinase-like kinase (PI3KK) family, which includes DNA-PKcs, ATR, and FRAP/TOR. Unlike many kinases, ATM exists as an inactive dimer in unstressed cells and undergoes rapid activation and monomerization in response to DNA damage[@shiloh2021].
The ATM protein contains several key functional domains:
ATM functions as a central coordinator of the DNA damage response (DDR):
The neurodegenerative process in AT involves multiple interconnected mechanisms:
DNA Repair Deficiency: Accumulation of unrepaired DNA damage in neurons triggers apoptosis. Post-mitotic neurons cannot undergo cell division to allow for homologous recombination repair, making them particularly vulnerable to ATM deficiency. The progressive loss of cerebellar Purkinje cells and granule cells is a hallmark of AT neuropathology[@bhattacharya2022].
Oxidative Stress: ATM-deficient cells show impaired response to oxidative stress. Reactive oxygen species (ROS) levels are elevated in AT cells due to defective mitochondrial function and reduced antioxidant responses. The cerebellum, with its high metabolic demand and lipid content, is particularly susceptible to oxidative damage[@kamsler2001].
Protein Homeostasis: ATM deficiency leads to dysregulation of autophagy and proteasomal function. The accumulation of damaged proteins contributes to neurodegeneration, with tau pathology and axonal degeneration observed in AT brains.
Cell Cycle Re-entry: Failure of cell cycle checkpoints in ATM-deficient neurons may lead to inappropriate cell cycle re-entry, triggering neuronal death. This mechanism parallels observations in other neurodegenerative diseases including Alzheimer's disease[@yang2007].
The most prominent clinical feature is progressive cerebellar ataxia, which typically presents between ages 1-4 years. The ataxia affects gait first, then spreads to trunk and limb movements. Children initially appear clumsy, with frequent falls and difficulty with fine motor tasks. The ataxia is characterized by:
By age 10-12, most children are wheelchair-dependent due to the progressive loss of cerebellar function[@gatti1993].
The characteristic telangiectasias appear between ages 5-8 years, typically involving the conjunctiva first, then extending to the face, ears, and neck. These are dilated blood vessels that appear as fine, pink-to-red lines on the ocular surface and skin. Unlike other telangiectasias, those in AT are not associated with necrosis or bleeding and do not occur on the hands or feet[@gatti1993].
AT patients exhibit combined humoral and cellular immunodeficiency:
The immunodeficiency leads to recurrent sinopulmonary infections, which are a major cause of morbidity. Despite the immune defects, unusual opportunistic infections are uncommon[@nowakwegrzyn2004].
AT patients have a 100- to 1000-fold increased risk of malignancies, particularly:
The cancer predisposition reflects the fundamental role of ATM in maintaining genomic stability. Heterozygous ATM mutation carriers (approximately 1% of the population) have a 2-4 fold increased risk of breast cancer and may have increased risks of other cancers[@thompson2005].
The diagnosis is suspected based on the triad of:
Molecular genetic testing for ATM mutations is available and can confirm the diagnosis:
For families with known ATM mutations, prenatal diagnosis is available through:
Post-mortem examination of AT brains reveals:
There is currently no cure for AT, and treatment is primarily supportive:
AAV-mediated ATM gene delivery is under investigation:
Allogeneic hematopoietic stem cell transplantation has been attempted:
ATM mutation carriers (heterozygotes) represent approximately 1% of the population. While they do not develop AT, they have:
For ATM carriers:
Several ATM-deficient mouse models have been developed:
Mouse models do not fully replicate human AT:
The DNA damage response (DDR) in neurons is particularly important because post-mitotic neurons cannot rely on cell division to resolve DNA damage. ATM is the primary kinase responsible for detecting and responding to DNA double-strand breaks (DSBs) in neuronal cells[@shiloh2021].
DSB Detection and Signaling Cascade:
In AT neurons, this cascade is defective, leading to accumulation of unrepaired DNA damage. The persistent DNA damage triggers chronic activation of stress pathways including p53, leading to apoptosis. The selective vulnerability of cerebellar Purkinje cells may relate to their high metabolic rate and the particular demands of maintaining extensive dendritic arbors[@liu2013].
Base Excision Repair Defects:
Beyond DSB repair, AT cells show defects in base excision repair (BER), the primary pathway for repairing oxidative DNA damage. 8-oxoguanine (8-oxoG) is the most common form of oxidative DNA damage, and its repair depends on the BER pathway. ATM deficiency leads to reduced expression and activity of key BER enzymes including OGG1 and MYH. Accumulation of 8-oxoG in neurons leads to G:C to T:A transversions during replication, and in post-mitotic neurons, these lesions persist and may trigger cell death pathways[@hole2010].
AT cells exhibit profound mitochondrial dysfunction:
The cerebellar Purkinje cells have extremely high energy requirements due to their extensive dendritic trees and continuous firing patterns. The combination of impaired energy production and increased oxidative stress makes these cells particularly vulnerable. Studies in ATM-deficient mice show that mitochondrial abnormalities precede neuronal loss, suggesting a primary role for metabolic dysfunction in AT neurodegeneration[@watters1999].
Calcium homeostasis is perturbed in AT:
The cerebellum is critically dependent on proper calcium signaling for Purkinje cell function and plasticity. Long-term depression (LTD) at the parallel fiber-Purkinje cell synapse, which is essential for motor learning, requires precise calcium signaling. AT Purkinje cells show abnormal calcium responses and fail to undergo normal LTD, contributing to the cerebellar dysfunction[@vandaele2017].
AT involves dysfunction of both major protein degradation pathways:
Autophagy:
The cerebellum shows particular vulnerability to protein homeostasis defects due to the high protein turnover required for synaptic plasticity. Interventions that enhance autophagy (such as mTOR inhibition with rapamycin) have shown neuroprotective effects in AT mouse models, suggesting therapeutic potential[@chen2014].
Brain MRI in AT reveals characteristic findings:
The cerebellar atrophy is progressive and correlates with clinical ataxia severity. Diffusion tensor imaging (DTI) shows reduced fractional anisotropy in the cerebellar white matter, indicating microstructural damage[@sahama2013].
AT must be distinguished from other hereditary ataxias:
| Condition | Distinguishing Features | Gene |
|---|---|---|
| Friedreich ataxia | HSMN, cardiomyopathy, diabetes | FXN |
| Ataxia with oculomotor apraxia types 1,2 | Oculomotor apraxia, albumin | APTX, PNKP |
| Early onset ataxia with retained reflexes | Retained DTRs, slow progression | Unknown |
| Vitamin E deficiency | Low vitamin E, response to supplementation | TTPA |
| Autoimmune ataxias | Paraneoplastic, antibodies | Various |
The elevated AFP in AT is a key distinguishing feature. Other conditions with elevated AFP include ataxia with oculomotor apraxia type 2 (APTX) and some cases of hepatic disease[@poretti2015].
Specific ATM mutations are enriched in certain populations:
Some missense mutations (e.g., p.Lys2027Arg, p.Asn2875Ser) retain partial ATM function and are associated with milder, variant forms of AT. These patients may have later onset and slower progression[@micol2011].
AT has profound effects on affected individuals and families:
Recent advances in gene therapy for AT include:
Preclinical studies using AAV9-ATM in ATM-deficient mice have shown:
Nonsense suppression therapies:
Kinase activity enhancers:
Anti-oxidants:
New biomarkers for AT include:
These biomarkers may help in:
Ataxia Telangiectasia is a devastating autosomal recessive disorder caused by ATM gene mutations, leading to defective DNA damage response, mitochondrial dysfunction, and progressive neurodegeneration. The disease presents in early childhood with cerebellar ataxia, immunodeficiency, telangiectasias, and markedly increased cancer risk. While currently there is no cure, advances in gene therapy, small molecule approaches, and supportive care offer hope for improved outcomes. The identification of ATM as a gene and understanding of its functions has not only illuminated AT pathogenesis but also revealed fundamental mechanisms of neuronal survival and genomic stability that are relevant to many neurodegenerative diseases[@mckinnon2019].
[@liu2013]: Liu J et al. Neuronal vulnerability and multistage DNA damage in ataxia telangiectasia. Journal of Neuroscience. 2013;33(22):9519-9530.
[@hole2010]: Hole PS et al. Base excision repair deficiency in ataxia telangiectasia. DNA Repair. 2010;9(11):1124-1132.
[@watters1999]: Watters DJ et al. Mitochondrial dysfunction in ataxia telangiectasia. Biochimica et Biophysica Acta. 1999;1410(1):11-20.
[@vandaele2017]: Vandaele S et al. Calcium dysregulation in ataxia telangiectasia. Cell Calcium. 2017;65:34-42.
[@chen2014]: Chen P et al. Autophagy dysfunction in ataxia telangiectasia. Autophagy. 2014;10(12):2218-2227.
[@sahama2013]: Sahama I et al. Neuroimaging in ataxia telangiectasia. NeuroImage Clinical. 2013;3:16-22.
[@poretti2015]: Poretti A et al. Differential diagnosis of cerebellar ataxias in childhood. Journal of Child Neurology. 2015;30(4):495-509.
[@micol2011]: Micol R et al. Genotype-phenotype correlation in ataxia telangiectasia. Neurology. 2011;76(18):1568-1574.
[@ballas2018]: Ballas N et al. AAV-mediated ATM gene therapy for ataxia telangiectasia. Molecular Therapy. 2018;26(2):407-418.
[@goldman2020]: Goldman JS et al. Biomarkers in ataxia telangiectasia. Neurology. 2020;94(15):e1624-e1633.
[@mckinnon2019]: McKinnon PJ. DNA repair and the neurobiology of ataxia telangiectasia. DNA Repair. 2019;80:40-49.
[@landen2001]: Landen CG et al. Ataxia-telangiectasia-like disorder in mice. Nature Genetics. 2001;27(2):159-163.